Medicare Enrolled
Dr. Yuanbin Chen, MD
Medical Oncology · Orlando, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chen?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chen
Dr. Yuanbin Chen is a medical oncology specialist in Orlando, FL, with 17 years of NPI registration. Based on federal Medicare data, Dr. Chen performed 91,099 Medicare services across 2,642 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chen received a total of $914,363 from 79 pharmaceutical and/or device companies across 1432 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chen is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 26% volume in FL
$914,363 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 174346 | Clear | January 31, 2027 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗91,099
Medicare services
Top 26% in FL for medical oncology
2,642
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,359 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 32,491 | $24 | $45 |
| Pembrolizumab injection (Keytruda) | 12,827 | $43 | $80 |
| Anti-nausea injection (fosaprepitant) | 11,550 | $0 | $3 |
| Paclitaxel chemotherapy injection | 5,676 | $0 | $0 |
| Injection, pemetrexed (pemfexy), 10 mg | 5,158 | $61 | $121 |
| Injection, ipilimumab, 1 mg | 4,904 | $130 | $245 |
| Injection, lanreotide, 1 mg | 3,840 | $43 | $103 |
| Dexamethasone injection (steroid) | 2,294 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,600 | $1 | $31 |
| Injection, bortezomib, 0.1 mg | 1,505 | $5 | $70 |
| Injection, etoposide, 10 mg | 1,022 | $1 | $2 |
| Blood draw (venipuncture) | 784 | $8 | $15 |
| Complete blood count (CBC) with differential | 755 | $8 | $26 |
| Comprehensive metabolic blood panel | 753 | $10 | $35 |
| Administration of chemotherapy into vein, 1 hour or less | 613 | $92 | $292 |
| Injection, carboplatin, 50 mg | 590 | $2 | $8 |
| Injection of additional new drug or substance into vein | 532 | $11 | $34 |
| Thyroid stimulating hormone (TSH) test | 388 | $16 | $57 |
| Office visit, established patient (30-39 min) | 293 | $91 | $189 |
| Injection, magnesium sulfate, per 500 mg | 271 | $1 | $1 |
| Office visit, established patient (20-29 min) | 255 | $62 | $133 |
| Magnesium level test | 224 | $7 | $23 |
| Injection, potassium chloride, per 2 meq | 210 | $0 | $0 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 172 | $75 | $70 |
| Administration of additional new drug or substance into vein, 1 hour or less | 168 | $46 | $142 |
| Injection, zoledronic acid, 1 mg | 140 | $6 | $25 |
| Adrenocorticotropic hormone (acth) level | 135 | $38 | $108 |
| Cortisol (hormone) measurement, total | 129 | $16 | $46 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 126 | $15 | $41 |
| Drug injection, under skin or into muscle | 112 | $10 | $38 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 111 | $21 | $66 |
| Administration of chemotherapy into vein, each additional hour | 109 | $20 | $47 |
| Free thyroxine (T4) test | 108 | $9 | $31 |
| Hospital follow-up visit, high complexity | 95 | $92 | $180 |
| Injection, diphenhydramine hcl, up to 50 mg | 95 | $1 | $2 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 93 | $53 | $123 |
| Lactate dehydrogenase (enzyme) level | 89 | $6 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 78 | $46 | $151 |
| Office visit, established patient, complex (40-54 min) | 75 | $132 | $264 |
| Infusion, normal saline solution , 1000 cc | 63 | $2 | $4 |
| Unclassified drugs | 56 | $1 | $2 |
| Hepatitis b core antibody measurement | 52 | $12 | $30 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 52 | $10 | $26 |
| Administration of additional new drug or substance into vein using push technique | 52 | $39 | $100 |
| Administration of chemotherapy into vein using push technique | 50 | $71 | $240 |
| Infusion into a vein for hydration, each additional hour | 48 | $9 | $26 |
| Infusion into a vein for hydration, 31-60 minutes | 46 | $24 | $84 |
| Hepatitis b surface antibody measurement | 42 | $11 | $27 |
| Creatine kinase (cardiac enzyme) level, total | 39 | $6 | $18 |
| Injection, alteplase recombinant, 1 mg | 36 | $69 | $132 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 34 | $1 | $3 |
| Prothrombin time test (blood clotting) | 28 | $4 | $13 |
| New patient office visit, complex (60-74 min) | 27 | $161 | $324 |
| Injection of drug or substance into vein | 21 | $25 | $83 |
| Declotting of central venous tube | 17 | $22 | $84 |
| Hepatitis c antibody measurement | 15 | $14 | $36 |
| Office visit, established patient (10-19 min) | 14 | $34 | $82 |
| Measurement of hepatitis a antibody | 13 | $12 | $31 |
| New patient office visit (45-59 min) | 13 | $127 | $285 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $16 | $35 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.5% high complexity
94.2% medium
5.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$914,363
Total received (2018-2024)
Avg $130,623/year across 7 years
Top 2% in FL for medical oncology
79
Companies
1,432
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$775,871 (84.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$130,198 (14.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,294 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$129,265
2023
$60,145
2022
$118,530
2021
$105,626
2020
$125,778
2019
$159,053
2018
$215,966
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$339,298
E.R. Squibb & Sons, L.L.C.
$162,371
Takeda Pharmaceuticals U.S.A., Inc.
$127,605
Amgen Inc.
$71,049
JAZZ PHARMACEUTICALS INC.
$60,032
Ipsen Bioscience Inc
$23,625
PFIZER INC.
$22,065
Merck Sharp & Dohme Corporation
$21,484
Lilly USA, LLC
$18,984
Genentech USA, Inc.
$15,172
Novartis Pharmaceuticals Corporation
$11,704
Ipsen Biopharmaceuticals, Inc
$5,805
Daiichi Sankyo Inc.
$4,926
Jazz Pharmaceuticals Inc.
$4,247
ARRAY BIOPHARMA INC
$3,585
Heron Therapeutics, Inc.
$3,002
EMD Serono, Inc.
$2,183
ABBVIE INC.
$1,917
Regeneron Healthcare Solutions, Inc.
$1,912
Merck Sharp & Dohme LLC
$1,909
Genentech, Inc.
$1,686
Celgene Corporation
$1,606
NOVARTIS PHARMACEUTICALS CORPORATION
$1,575
G1 Therapeutics, Inc.
$1,537
Janssen Scientific Affairs, LLC
$1,010
GENZYME CORPORATION
$280
Janssen Biotech, Inc.
$266
Foundation Medicine, Inc.
$261
Incyte Corporation
$241
Eli Lilly and Company
$200
Eisai Inc.
$180
Boehringer Ingelheim Pharmaceuticals, Inc.
$174
Array BioPharma Inc.
$170
Seagen Inc.
$153
Gilead Sciences, Inc.
$139
Pharmacyclics LLC, An AbbVie Company
$134
Pharmacyclics LLC, an AbbVie Company
$132
Genmab U.S., Inc.
$112
Mirati Therapeutics, Inc.
$97
Exelixis Inc.
$89
Karyopharm Therapeutics Inc.
$83
EISAI INC.
$81
AbbVie Inc.
$76
Astellas Pharma US Inc
$76
Rigel Pharmaceuticals, Inc.
$70
Kite Pharma, Inc.
$69
Janssen Pharmaceuticals, Inc
$56
Alexion Pharmaceuticals, Inc.
$54
TESARO, Inc.
$54
GlaxoSmithKline, LLC.
$48
Bayer HealthCare Pharmaceuticals Inc.
$43
Acrotech Biopharma Inc.
$41
Bayer Healthcare Pharmaceuticals Inc.
$40
Puma Biotechnology, Inc.
$39
Taiho Oncology, Inc.
$38
Aadi Bioscience, Inc.
$38
Acrotech Biopharma LLC
$36
TerSera Therapeutics LLC
$33
Kyowa Kirin, Inc.
$32
Agios Pharmaceuticals, Inc.
$31
Deciphera Pharmaceuticals Inc.
$31
PharmaEssentia USA Corporation
$30
Amneal Pharmaceuticals LLC
$29
BeiGene USA, Inc.
$28
SERVIER PHARMACEUTICALS LLC
$28
Progenics Pharmaceuticals, Inc.
$25
Novo Nordisk Inc
$25
Teva Pharmaceuticals USA, Inc.
$25
Alnylam Pharmaceuticals Inc.
$24
Bristol-Myers Squibb Company
$23
Mylan Institutional Inc.
$20
Seattle Genetics, Inc.
$18
Pharmacosmos Therapeutics Inc.
$17
Stemline Therapeutics Inc.
$17
ADC Therapeutics America, Inc.
$16
AbbVie, Inc.
$14
Partner Therapeutics, Inc.
$13
Clovis Oncology, Inc.
$13
Verastem, Inc.
$11
Top 3 companies account for 68.8% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AVASTIN · Abraxane · Actemra · Alecensa · Aliqopa · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EXKIVITY · Enhertu · Epkinly · FASLODEX · FOLOTYN · FOUNDATIONONE · FRUZAQLA · Fabhalta · Fyarro · GARDASIL 9 · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMDELLTRA (AMG 757) · IMFINZI · IMLYGIC · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · Lupron Depot · MEKINIST · MEKTOVI · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · NERLYNX · NINLARO · NOXAFIL · Nerlynx · Neulasta · NovoSeven RT · Nplate · ONGLYZA · ONIVYDE · ONUREG · OPDIVO · OPDUALAG · Onivyde · Orserdu · PADCEV · PLUVICTO · PYLARIFY · PYRUKYND · Perjeta · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Reblozyl · Revlimid · Rituxan Hycela · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · Stivarga · TAFINLAR · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEPMETKO · TIBSOVO · TIVDAK · TUMOR LYSIS SYNDROME - DISEASE · Tarceva · Tavalisse · Tazverik · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VIZIMPRO · VOTRIENT · VYXEOS · Vanflyta · Vectibix · Vitrakvi · XALKORI · XARELTO · XPOVIO · XTANDI · Xtandi · Yescarta · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (85%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for medical oncology in FL.
Equivalent to $1,004 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
23
Per 100K population
1.6
County median income
$77,011
Nearest hospital
ORLANDO HEALTH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Chen is a mixed practice specialist, with above-average Medicare volume (top 26% in FL), with speaking/promotional industry engagement in the top 2% of FL peers, with 17 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Chen experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Chen performed 32,491 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chen receive payments from pharmaceutical companies?
Yes. Dr. Chen received a total of $914,363 from 79 companies across 1,432 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chen's costs compare to other medical oncologists in Orlando?
Dr. Chen's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Orlando
Browse medical oncologists in Orlando ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in FL
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in FL
Which FL medical oncologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology